Formulation and Evaluation of Chronothetapeutic beads using Antiasthematic agent Montelukast Sodium

Abstract

This study explores the development of oral controlled release systems for Montelukast sodium aimed at treating nocturnal asthma. Utilizing multiparticulate systems like chitosan and sodium alginate beads, the formulations maintain therapeutic drug concentrations over extended periods. Characterization confirmed the drug's integrity through melting point, UV scanning, and FTIR spectroscopy. Beads were created with varying drug-to-polymer ratios, achieving encapsulation efficiencies of 25.17% to 78.28%. Chitosan-based formulations exhibited superior mucoadhesion due to its positive charge. In vitro drug release studies demonstrated sustained release with a lag time of up to 6 hours in Eudragit S-100 coated beads, following zero-order kinetics. Stability studies indicated formulations remained stable at 40°C and 75% humidity for three months. The results indicate that these chronotherapeutic beads effectively deliver Montelukast sodium, optimizing drug release for patients with nocturnal asthma and enhancing therapeutic efficacy and compliance.